A quantitative assessment of the risks and cost savings of forgoing histologic examination of diminutive polyps

W. R. Kessler, T. F. Imperiale, R. W. Klein, R. C. Wielage, D. K. Rex

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Background and aims: Endoscopic prediction of polyp histology is rapidly improving to the point where it may not be necessary to submit all polyps for formal histologic assessment. This study aimed to quantify the expected costs and outcomes of removing diminutive polyps without subsequent pathologic assessment. Methods: Cross-sectional analysis of a colonoscopy database for polyp histology; decision models that quantify effects on guideline-recommended surveillance and subsequent costs and consequences. The database was composed of consecutive colonoscopies from 1999 to 2004 at a single-institution tertiary care center. Patients were those found to have at least one diminutive polyp removed during colonoscopy, irrespective of indication. The main outcome measurements include up-front cost savings resulting from forgoing pathologic assessment; frequency and cost of incorrect surveillance intervals based on errors in histologic assessment; number needed to harm (NNH) for perforation and/or interval cancer. Results: Incorrect surveillance intervals were recommended in 1.9% of cases when tissue was submitted for pathologic assessment and 11.8% of cases when it was not. Based on the annual volume of colonoscopy in the US, the annual up-front cost savings of forgoing the pathologic assessment would exceed a billion dollars. An upper estimate on the downstream costs and consequences of forgoing pathology suggests that less than 10% of the up-front savings would be offset and the NNH exceeds 11000. Conclusion: Endoscopic diagnosis of polyp histology during colonoscopy and forgoing pathologic examination would result in substantial up-front cost savings. Downstream consequences of the resulting incorrect surveillance intervals appear to be negligible.

Original languageEnglish (US)
Pages (from-to)683-691
Number of pages9
JournalEndoscopy
Volume43
Issue number8
DOIs
StatePublished - May 30 2011

Fingerprint

Cost Savings
Polyps
Colonoscopy
Costs and Cost Analysis
Histology
Databases
Tertiary Care Centers
Cross-Sectional Studies
Guidelines
Pathology
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A quantitative assessment of the risks and cost savings of forgoing histologic examination of diminutive polyps. / Kessler, W. R.; Imperiale, T. F.; Klein, R. W.; Wielage, R. C.; Rex, D. K.

In: Endoscopy, Vol. 43, No. 8, 30.05.2011, p. 683-691.

Research output: Contribution to journalArticle

@article{b0bd3711432c42b081fdf4607b1df8c7,
title = "A quantitative assessment of the risks and cost savings of forgoing histologic examination of diminutive polyps",
abstract = "Background and aims: Endoscopic prediction of polyp histology is rapidly improving to the point where it may not be necessary to submit all polyps for formal histologic assessment. This study aimed to quantify the expected costs and outcomes of removing diminutive polyps without subsequent pathologic assessment. Methods: Cross-sectional analysis of a colonoscopy database for polyp histology; decision models that quantify effects on guideline-recommended surveillance and subsequent costs and consequences. The database was composed of consecutive colonoscopies from 1999 to 2004 at a single-institution tertiary care center. Patients were those found to have at least one diminutive polyp removed during colonoscopy, irrespective of indication. The main outcome measurements include up-front cost savings resulting from forgoing pathologic assessment; frequency and cost of incorrect surveillance intervals based on errors in histologic assessment; number needed to harm (NNH) for perforation and/or interval cancer. Results: Incorrect surveillance intervals were recommended in 1.9{\%} of cases when tissue was submitted for pathologic assessment and 11.8{\%} of cases when it was not. Based on the annual volume of colonoscopy in the US, the annual up-front cost savings of forgoing the pathologic assessment would exceed a billion dollars. An upper estimate on the downstream costs and consequences of forgoing pathology suggests that less than 10{\%} of the up-front savings would be offset and the NNH exceeds 11000. Conclusion: Endoscopic diagnosis of polyp histology during colonoscopy and forgoing pathologic examination would result in substantial up-front cost savings. Downstream consequences of the resulting incorrect surveillance intervals appear to be negligible.",
author = "Kessler, {W. R.} and Imperiale, {T. F.} and Klein, {R. W.} and Wielage, {R. C.} and Rex, {D. K.}",
year = "2011",
month = "5",
day = "30",
doi = "10.1055/s-0030-1256381",
language = "English (US)",
volume = "43",
pages = "683--691",
journal = "Endoscopy",
issn = "0013-726X",
publisher = "Georg Thieme Verlag",
number = "8",

}

TY - JOUR

T1 - A quantitative assessment of the risks and cost savings of forgoing histologic examination of diminutive polyps

AU - Kessler, W. R.

AU - Imperiale, T. F.

AU - Klein, R. W.

AU - Wielage, R. C.

AU - Rex, D. K.

PY - 2011/5/30

Y1 - 2011/5/30

N2 - Background and aims: Endoscopic prediction of polyp histology is rapidly improving to the point where it may not be necessary to submit all polyps for formal histologic assessment. This study aimed to quantify the expected costs and outcomes of removing diminutive polyps without subsequent pathologic assessment. Methods: Cross-sectional analysis of a colonoscopy database for polyp histology; decision models that quantify effects on guideline-recommended surveillance and subsequent costs and consequences. The database was composed of consecutive colonoscopies from 1999 to 2004 at a single-institution tertiary care center. Patients were those found to have at least one diminutive polyp removed during colonoscopy, irrespective of indication. The main outcome measurements include up-front cost savings resulting from forgoing pathologic assessment; frequency and cost of incorrect surveillance intervals based on errors in histologic assessment; number needed to harm (NNH) for perforation and/or interval cancer. Results: Incorrect surveillance intervals were recommended in 1.9% of cases when tissue was submitted for pathologic assessment and 11.8% of cases when it was not. Based on the annual volume of colonoscopy in the US, the annual up-front cost savings of forgoing the pathologic assessment would exceed a billion dollars. An upper estimate on the downstream costs and consequences of forgoing pathology suggests that less than 10% of the up-front savings would be offset and the NNH exceeds 11000. Conclusion: Endoscopic diagnosis of polyp histology during colonoscopy and forgoing pathologic examination would result in substantial up-front cost savings. Downstream consequences of the resulting incorrect surveillance intervals appear to be negligible.

AB - Background and aims: Endoscopic prediction of polyp histology is rapidly improving to the point where it may not be necessary to submit all polyps for formal histologic assessment. This study aimed to quantify the expected costs and outcomes of removing diminutive polyps without subsequent pathologic assessment. Methods: Cross-sectional analysis of a colonoscopy database for polyp histology; decision models that quantify effects on guideline-recommended surveillance and subsequent costs and consequences. The database was composed of consecutive colonoscopies from 1999 to 2004 at a single-institution tertiary care center. Patients were those found to have at least one diminutive polyp removed during colonoscopy, irrespective of indication. The main outcome measurements include up-front cost savings resulting from forgoing pathologic assessment; frequency and cost of incorrect surveillance intervals based on errors in histologic assessment; number needed to harm (NNH) for perforation and/or interval cancer. Results: Incorrect surveillance intervals were recommended in 1.9% of cases when tissue was submitted for pathologic assessment and 11.8% of cases when it was not. Based on the annual volume of colonoscopy in the US, the annual up-front cost savings of forgoing the pathologic assessment would exceed a billion dollars. An upper estimate on the downstream costs and consequences of forgoing pathology suggests that less than 10% of the up-front savings would be offset and the NNH exceeds 11000. Conclusion: Endoscopic diagnosis of polyp histology during colonoscopy and forgoing pathologic examination would result in substantial up-front cost savings. Downstream consequences of the resulting incorrect surveillance intervals appear to be negligible.

UR - http://www.scopus.com/inward/record.url?scp=79961128559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961128559&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1256381

DO - 10.1055/s-0030-1256381

M3 - Article

C2 - 21623556

AN - SCOPUS:79961128559

VL - 43

SP - 683

EP - 691

JO - Endoscopy

JF - Endoscopy

SN - 0013-726X

IS - 8

ER -